gemfibrozil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1285 25812-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemfibrosil
  • gemfibrozil
  • decrelip
  • lopizid
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
  • Molecular weight: 250.34
  • Formula: C15H22O3
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.95
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 79.89 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1981 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 232.33 14.07 123 10422 43828 63434649
Drug hypersensitivity 70.95 14.07 158 10387 310529 63167948
Blood triglycerides increased 60.43 14.07 33 10512 12455 63466022
Coronary artery disease 58.19 14.07 46 10499 32331 63446146
Myocardial infarction 50.42 14.07 72 10473 99821 63378656
Blood creatine phosphokinase increased 49.94 14.07 41 10504 30389 63448088
Acute interstitial pneumonitis 43.70 14.07 12 10533 692 63477785
Cardiac failure congestive 40.00 14.07 62 10483 92371 63386106
Myalgia 37.32 14.07 78 10467 146451 63332026
Drug interaction 36.81 14.07 102 10443 229029 63249448
Cerebrovascular accident 35.43 14.07 64 10481 107960 63370517
Myopathy 34.24 14.07 22 10523 11169 63467308
Pancreatitis 33.45 14.07 41 10504 49014 63429463
Lip infection 33.33 14.07 7 10538 126 63478351
Off label use 31.08 14.07 40 10505 674422 62804055
Pancreatitis acute 29.50 14.07 29 10516 27137 63451340
Drug intolerance 26.69 14.07 9 10536 308652 63169825
Diabetes mellitus 24.92 14.07 38 10507 55772 63422705
Blood glucose increased 24.18 14.07 47 10498 83709 63394768
Drug ineffective 22.83 14.07 93 10452 1044672 62433805
Synovitis 21.07 14.07 3 10542 186915 63291562
Tendon rupture 19.93 14.07 14 10531 8225 63470252
Bronchitis viral 18.86 14.07 7 10538 1069 63477408
Arthropathy 18.37 14.07 8 10537 234784 63243693
Diabetes mellitus inadequate control 18.03 14.07 17 10528 15109 63463368
Infected bite 17.63 14.07 8 10537 2034 63476443
Chronic kidney disease 17.63 14.07 29 10516 45369 63433108
Microalbuminuria 16.60 14.07 5 10540 401 63478076
Joint swelling 16.57 14.07 18 10527 327648 63150829
Blood urea increased 16.31 14.07 21 10524 26358 63452119
Hyperlipidaemia 16.07 14.07 18 10527 19553 63458924
Hypertriglyceridaemia 15.99 14.07 11 10534 6248 63472229
Transient ischaemic attack 15.86 14.07 25 10520 37728 63440749
Wound 15.49 14.07 4 10541 163259 63315218
Infusion related reaction 15.41 14.07 11 10534 245510 63232967
Hypoglycaemia 15.30 14.07 32 10513 60033 63418444
Maternal exposure during pregnancy 14.97 14.07 9 10536 220053 63258424
Hypophagia 14.97 14.07 22 10523 31237 63447240
Renal failure 14.72 14.07 48 10497 117604 63360873
Granulocytopenia 14.57 14.07 10 10535 5662 63472815
Blood creatine phosphokinase MB increased 14.55 14.07 6 10539 1210 63477267
Myositis 14.19 14.07 12 10533 9254 63469223

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 550.36 12.74 350 14700 67813 34874068
Acute kidney injury 118.19 12.74 342 14708 304646 34637235
Blood creatine phosphokinase increased 113.40 12.74 117 14933 44740 34897141
Myalgia 99.83 12.74 150 14900 83960 34857921
Blood triglycerides increased 97.43 12.74 66 14984 14093 34927788
Coronary artery disease 76.47 12.74 99 14951 48206 34893675
Myocardial infarction 64.20 12.74 153 14897 120932 34820949
Drug hypersensitivity 56.58 12.74 114 14936 80415 34861466
Off label use 56.10 12.74 59 14991 419465 34522416
Polymyositis 53.43 12.74 21 15029 1432 34940449
Drug interaction 50.87 12.74 212 14838 225734 34716147
Cardiac failure congestive 50.49 12.74 111 14939 83159 34858722
Blood cholesterol increased 42.08 12.74 48 15002 20495 34921386
Pancreatitis 38.63 12.74 64 14986 38827 34903054
Drug level below therapeutic 33.52 12.74 24 15026 5591 34936290
Drug ineffective 32.15 12.74 96 14954 456655 34485226
International normalised ratio increased 32.02 12.74 66 14984 47261 34894620
Myopathy 30.72 12.74 31 15019 11523 34930358
Drug abuse 26.99 12.74 5 15045 99091 34842790
Hyperglycaemia 26.63 12.74 55 14995 39425 34902456
Haemodialysis 25.74 12.74 27 15023 10499 34931382
Chromaturia 24.91 12.74 31 15019 14489 34927392
Granulocytopenia 23.95 12.74 21 15029 6546 34935335
Chronic kidney disease 23.89 12.74 54 14996 41156 34900725
Blood glucose increased 22.95 12.74 72 14978 66646 34875235
Type 2 diabetes mellitus 22.49 12.74 31 15019 16001 34925880
General physical health deterioration 22.07 12.74 14 15036 128255 34813626
Thunderclap headache 21.46 12.74 6 15044 139 34941742
Asthenia 20.72 12.74 178 14872 245073 34696808
Angina unstable 20.18 12.74 25 15025 11628 34930253
Myositis 19.48 12.74 25 15025 12045 34929836
Iron deficiency anaemia 19.25 12.74 23 15027 10306 34931575
Blood glucose decreased 19.18 12.74 26 15024 13211 34928670
Angioedema 18.44 12.74 46 15004 37328 34904553
Hypertriglyceridaemia 17.74 12.74 20 15030 8428 34933453
Treatment noncompliance 17.61 12.74 38 15012 28062 34913819
Product use in unapproved indication 17.39 12.74 15 15035 117484 34824397
Arteriosclerosis coronary artery 17.30 12.74 24 15026 12461 34929420
Tricuspid valve incompetence 17 12.74 21 15029 9739 34932142
Lacrimation decreased 16.96 12.74 3 15047 6 34941875
Fanconi syndrome 16.77 12.74 10 15040 1710 34940171
Erosive duodenitis 16.75 12.74 10 15040 1714 34940167
Blood creatinine increased 16.71 12.74 83 14967 94893 34846988
Death 16.61 12.74 102 14948 397947 34543934
Intentional product use issue 16.32 12.74 3 15047 59813 34882068
Pyrexia 15.68 12.74 82 14968 332931 34608950
Muscular weakness 15.24 12.74 67 14983 72830 34869051
Chest pain 15.20 12.74 100 14950 126662 34815219
Otitis externa 15.14 12.74 8 15042 1085 34940796
Pneumonia haemophilus 14.88 12.74 6 15044 437 34941444
Supraventricular tachycardia 14.85 12.74 21 15029 11096 34930785
Breast neoplasm 14.72 12.74 3 15047 16 34941865
Reversible cerebral vasoconstriction syndrome 14.70 12.74 6 15044 451 34941430
Hyperlipidaemia 14.54 12.74 24 15026 14505 34927376
Renal tubular necrosis 14.49 12.74 25 15025 15655 34926226
Interstitial lung disease 14.49 12.74 5 15045 65277 34876604
C-reactive protein increased 14.16 12.74 3 15047 54095 34887786
Coronary artery stenosis 14.10 12.74 19 15031 9597 34932284
Metabolic acidosis 13.98 12.74 46 15004 43634 34898247
Hyperlactacidaemia 13.81 12.74 11 15039 3005 34938876
Paralysis 13.81 12.74 15 15035 6067 34935814
Renal failure 13.31 12.74 99 14951 130458 34811423
Intervertebral disc displacement 12.87 12.74 4 15046 135 34941746
Aortic valve sclerosis 12.86 12.74 7 15043 1007 34940874
High density lipoprotein decreased 12.77 12.74 11 15039 3349 34938532

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 734.11 12.66 411 20710 102720 79620547
Blood creatine phosphokinase increased 168.95 12.66 140 20981 65950 79657317
Blood triglycerides increased 163.34 12.66 89 21032 20951 79702316
Coronary artery disease 147.50 12.66 129 20992 65345 79657922
Acute kidney injury 142.00 12.66 377 20744 519027 79204240
Myocardial infarction 130.14 12.66 199 20922 183930 79539337
Myalgia 121.95 12.66 194 20927 185447 79537820
Cardiac failure congestive 88.25 12.66 145 20976 142257 79581010
Drug hypersensitivity 83.46 12.66 219 20902 298697 79424570
Off label use 82.19 12.66 72 21049 907143 78816124
Drug interaction 80.41 12.66 267 20854 414916 79308351
Pancreatitis 62.91 12.66 84 21037 68491 79654776
Myopathy 59.78 12.66 47 21074 20516 79702751
Drug ineffective 55.85 12.66 128 20993 1080785 78642482
Polymyositis 48.33 12.66 21 21100 3015 79720252
Granulocytopenia 44.16 12.66 31 21090 11400 79711867
Hyperlipidaemia 38.94 12.66 41 21080 26052 79697215
Hyperglycaemia 38.73 12.66 68 21053 70267 79653000
Myositis 37.67 12.66 35 21086 19133 79704134
Drug intolerance 36.88 12.66 12 21109 264107 79459160
International normalised ratio increased 36.80 12.66 74 21047 84647 79638620
Chromaturia 35.85 12.66 39 21082 25707 79697560
Blood glucose increased 33.81 12.66 86 21035 114889 79608378
Chronic kidney disease 32.66 12.66 61 21060 66093 79657174
Hypertriglyceridaemia 32.54 12.66 27 21094 12713 79710554
Acute interstitial pneumonitis 31.67 12.66 12 21109 1211 79722056
Blood creatinine increased 31.04 12.66 101 21020 154956 79568311
Renal failure 30.07 12.66 119 21002 200849 79522418
Treatment failure 29.19 12.66 5 21116 170481 79552786
Pancreatitis acute 28.67 12.66 49 21072 49555 79673712
Haemodialysis 27.92 12.66 29 21092 18139 79705128
Angioedema 27.90 12.66 62 21059 75973 79647294
Cerebrovascular accident 27.43 12.66 97 21024 155195 79568072
Drug abuse 27.36 12.66 5 21116 162686 79560581
Lip infection 27.21 12.66 7 21114 194 79723073
General physical health deterioration 27.10 12.66 20 21101 275218 79448049
Angina unstable 26.51 12.66 27 21094 16500 79706767
Joint swelling 25.89 12.66 23 21098 288623 79434644
Hypoglycaemia 25.82 12.66 72 21049 101522 79621745
Muscular weakness 25.53 12.66 97 21024 160632 79562635
Blood glucose decreased 25.38 12.66 33 21088 26201 79697066
Acute myocardial infarction 25.16 12.66 60 21061 76976 79646291
Pyrexia 24.99 12.66 94 21027 678615 79044652
Infusion related reaction 23.62 12.66 16 21105 230221 79493046
Arteriosclerosis coronary artery 23.10 12.66 26 21095 17790 79705477
Treatment noncompliance 21.91 12.66 45 21076 52223 79671044
Renal cyst 21.71 12.66 23 21098 14709 79708558
Lower respiratory tract infection 21.66 12.66 4 21117 129216 79594051
High density lipoprotein decreased 21.25 12.66 14 21107 4641 79718626
Coronary artery stenosis 21.14 12.66 21 21100 12463 79710804
Product use issue 20.97 12.66 15 21106 209807 79513460
Hyperkalaemia 20.66 12.66 72 21049 114326 79608941
Chest pain 20.22 12.66 136 20985 282168 79441099
Cardiac disorder 20.17 12.66 50 21071 65707 79657560
Acute coronary syndrome 19.54 12.66 26 21095 21107 79702160
Intentional product use issue 19.38 12.66 8 21113 152104 79571163
Erosive duodenitis 19.37 12.66 10 21111 2107 79721160
Blood urea increased 19.28 12.66 41 21080 48749 79674518
Condition aggravated 18.69 12.66 69 21052 501055 79222212
Thunderclap headache 18.25 12.66 6 21115 399 79722868
Rheumatoid arthritis 18.22 12.66 17 21104 208453 79514814
Blood cholesterol increased 18.08 12.66 56 21065 83664 79639603
Hypophagia 17.78 12.66 38 21083 45329 79677938
C-reactive protein increased 17.76 12.66 6 21115 129021 79594246
Intervertebral disc displacement 17.65 12.66 6 21115 443 79722824
Metabolic acidosis 17.64 12.66 55 21066 82474 79640793
Iron deficiency anaemia 17.04 12.66 27 21094 25645 79697622
Blood creatine phosphokinase MB increased 16.72 12.66 10 21111 2801 79720466
Wound 16.70 12.66 5 21116 116174 79607093
Fanconi syndrome 16.58 12.66 10 21111 2846 79720421
Tricuspid valve incompetence 16.33 12.66 23 21098 19689 79703578
Maternal exposure during pregnancy 16.11 12.66 8 21113 136530 79586737
Type 2 diabetes mellitus 16.03 12.66 42 21079 57080 79666187
Coronary artery occlusion 15.97 12.66 20 21101 15295 79707972
Liver function test abnormal 15.70 12.66 45 21076 64430 79658837
Myoglobinuria 15.55 12.66 7 21114 1093 79722174
Diabetes mellitus inadequate control 15.40 12.66 25 21096 24239 79699028
Carotid artery stenosis 15.32 12.66 15 21106 8743 79714524
Bronchitis viral 15.06 12.66 7 21114 1176 79722091
Ischaemic cardiomyopathy 15.02 12.66 14 21107 7681 79715586
Product complaint 14.84 12.66 18 21103 13331 79709936
Peripheral swelling 14.58 12.66 31 21090 269586 79453681
Tendon rupture 14.55 12.66 17 21104 12109 79711158
Infected bite 14.52 12.66 8 21113 1922 79721345
Hepatic steatosis 14.09 12.66 31 21090 37707 79685560
Aspartate aminotransferase increased 13.91 12.66 73 21048 138568 79584699
Alopecia 13.90 12.66 25 21096 231330 79491937
Diabetes mellitus 13.86 12.66 49 21072 78341 79644926
Mitral valve incompetence 13.67 12.66 26 21095 28539 79694728
COVID-19 13.61 12.66 13 21108 157661 79565606
Erectile dysfunction 13.49 12.66 18 21103 14646 79708621
Asthenia 13.46 12.66 200 20921 511489 79211778
Myocardial ischaemia 13.18 12.66 24 21097 25495 79697772
Otitis externa 12.93 12.66 8 21113 2382 79720885
Arthropathy 12.68 12.66 17 21104 177094 79546173

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
FDA CS M0199111 PPAR alpha
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
CHEBI has role CHEBI:35679 antilipemic drugs
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
MeSH PA D000963 Antimetabolites
MeSH PA D065687 Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertriglyceridemia indication 302870006
Primary Prevention of Coronary Heart Disease indication
Hypoalphalipoproteinemia off-label use 190785000
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Leukopenia contraindication 84828003 DOID:615
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.23 IUPHAR CHEMBL
Transthyretin Secreted Kd 7 CHEMBL
Cytochrome P450 2C8 Enzyme Ki 5.74 WOMBAT-PK
Cytochrome P450 2C9 Enzyme Ki 4.52 WOMBAT-PK
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor EC50 4.17 CHEMBL
Lipoprotein lipase Enzyme WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1 Unclassified Ki 5.14 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 5.73 CHEMBL

External reference:

IDSource
4018639 VUID
N0000146952 NUI
D00334 KEGG_DRUG
4018639 VANDF
C0017245 UMLSCUI
CHEBI:5296 CHEBI
4TX PDB_CHEM_ID
CHEMBL457 ChEMBL_ID
DB01241 DRUGBANK_ID
D015248 MESH_DESCRIPTOR_UI
3463 PUBCHEM_CID
3439 IUPHAR_LIGAND_ID
3899 INN_ID
Q8X02027X3 UNII
4719 RXNORM
4778 MMSL
523 MMSL
d00245 MMSL
002050 NDDF
35282000 SNOMEDCT_US
387189002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 18 sections
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9130 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9707 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-8354 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-8354 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 10544-569 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 16571-784 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil Human Prescription Drug Label 1 16714-101 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 21695-732 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 24658-260 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 31722-128 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 31722-225 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 33261-146 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-090 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-772 TABLET, FILM COATED 600 mg ORAL ANDA 21 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43602-452 TABLET 600 mg ORAL ANDA 10 sections
Gemfibrozil Human Prescription Drug Label 1 50090-2450 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-2902 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 50090-5808 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 50090-5808 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 11 sections